PUBLICATIONS

PUBLICATIONS

  • 10

    LDI, A Lipid Droplet Inhibitor, Disrupts Lipid Accumulation and Modulates Hepatic Lipid Profiles in Fatty Liver

    ADVANCED MATERIALS. 2025. Impact factor: 26.8

    Seunghee Kim, Yeojin Kim, Sanjita Paudel, In Young Kang, Suyeon Kim, Jeesoo Kim,Sunmi Park, Seung-Hoi Koo, Hyun Sung Kim, Dae Won Jun,* Jinyoung Park,*Hyunbeom Lee,* and Joonseok Lee*

    Link
  • 9

    Efficacy and safety of time-restricted eating in metabolic dysfunction-associated steatotic liver disease

    Journal of Hepatology. 2025. Impact factor: 33.0

    Joo Hyun Oh, Eileen L. Yoon, Huiyul Park, Seungmin Lee, Ae Jeong Jo, Seon Cho, Eunjoo Kwon, Eun-Hee Nah, Jun-Hyuk Lee, Jung Hwan Park, Sang Bong Ahn, Dae Won Jun

    Link
  • 8

    Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF- κB signaling pathways

    Clinical and Molecular Hepatology. 2022. Impact factor: 16.9

    Seung Min Lee, Dong Hee Koh, Dae Won Jun, Yoon Jin Roh, Hyeon Tae Kang, Ju Hee Oh, Hyun Sung Kim

    Link
  • 7

    Discovery of dipeptidyl peptidase-4 inhibitor specific biomarker in non-alcoholic fatty liver disease mouse models using modified basket trial

    Clinical and Molecular Hepatology. 2022. Impact factor: 16.9

    Ju Hee Oh, Dae Won Jun, Hye Young Kim, Seung Min Lee, Eileen L Yoon, Jungwook Hwang, Jung Hwan Park, Hanbi Lee, Wankyu Kim, Hyunsung Kim

    Link
  • 6

    Diagnostic Performance of Noninvasive Tests in Patients with MetALD in a Health Check-up Cohort

    Journal of Hepatology. 2024. Impact factor: 33.0

    Joo Hyun Oh, Sang Bong Ahn, Seon Cho, Eun-Hee Nah, Eileen L. Yoon, Dae Won Jun

    Link
  • 5

    Do we need a new cut-off for FIB-4 in the metabolic dysfunction-associated fatty liver disease era?

    Journal of Hepatology. 2021. Impact factor: 33.0

    Huiyul Park, Eileen L. Yoon, Seon Cho, Eun-Hee Nah, Dae Won Jun

    Link
  • 4

    Discovering Heterogeneous Leukocytes Subsets Associated With Alcoholic Steatohepatitis by scRNAseq Analysis

    MedComm 2025. Impact factor: 10.7

    Haribalan Perumalsamy, Sehee Park, Ji Eun Kim, Xiao Xiao, Hye Young Kim, Dae Won Jun, Tae-Hyun Yoon

    Link
  • 3

    Necroptosis signaling in liver diseases: An update

    Pharmacol Res. 2019. Impact factor: 10.5

    Waqar Khalid Saeed, Dae Won Jun, Kiseok Jang, Dong Hee Koh

    Link
  • 2

    Diabetes is the strongest risk factor of hepatic fibrosis in lean patients with non-alcoholic fatty liver disease.

    GUT. 2021. Impact factor: 23.0

    Huiyul Park, Eileen L Yoon, Seon Cho, Dae Won Jun, Eun-Hee Nah

    Link
  • 1

    Viewpoint: necroptosis influences the type of liver cancer via changes of hepatic microenvironment

    Hepatobiliary Surg Nutr. 2019. Impact factor: 7.8

    Waqar K Saeed, Dae Won Jun

    Link